Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies
US-2019022037-A1 · Jan 24, 2019 · US
Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies
US10654813B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10654813-B2 |
| Application number | US-201816153249-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 5, 2018 |
| Priority date | Jan 10, 2008 |
| Publication date | May 19, 2020 |
| Grant date | May 19, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: Structure
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom · CPC title
- C07D249/06Primary
with aryl radicals directly attached to ring atoms · CPC title
of the kidneys · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10654813B2 cover?
- Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.
- Who is the assignee on this patent?
- Centre Nat Rech Scient, Inst Curie, Univ Montpellier
- What technology area does this patent fall under?
- Primary CPC classification C07D249/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).